MX2022009352A - Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus. - Google Patents

Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus.

Info

Publication number
MX2022009352A
MX2022009352A MX2022009352A MX2022009352A MX2022009352A MX 2022009352 A MX2022009352 A MX 2022009352A MX 2022009352 A MX2022009352 A MX 2022009352A MX 2022009352 A MX2022009352 A MX 2022009352A MX 2022009352 A MX2022009352 A MX 2022009352A
Authority
MX
Mexico
Prior art keywords
hemi
hepatitis
sulfate salt
nucleotide
virus
Prior art date
Application number
MX2022009352A
Other languages
Spanish (es)
Inventor
Adel Moussa
Jean - Pierre Sommadossi
Original Assignee
Atea Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62977563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022009352(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atea Pharmaceuticals Inc filed Critical Atea Pharmaceuticals Inc
Publication of MX2022009352A publication Critical patent/MX2022009352A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Storage Device Security (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A hemi-sulfate salt of the structure: [Formula should be inserted here] to treat a host infected with hepatitis C, as well as pharmaceutical compositions and dosage forms, including solid dosage forms, thereof.
MX2022009352A 2017-02-01 2019-07-31 Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus. MX2022009352A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762453437P 2017-02-01 2017-02-01
US201762469912P 2017-03-10 2017-03-10
US201762488366P 2017-04-21 2017-04-21
US201762575248P 2017-10-20 2017-10-20

Publications (1)

Publication Number Publication Date
MX2022009352A true MX2022009352A (en) 2022-09-02

Family

ID=62977563

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019009114A MX2019009114A (en) 2017-02-01 2018-01-31 Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus.
MX2022009352A MX2022009352A (en) 2017-02-01 2019-07-31 Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019009114A MX2019009114A (en) 2017-02-01 2018-01-31 Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus.

Country Status (18)

Country Link
US (6) US10519186B2 (en)
EP (1) EP3577124A4 (en)
JP (2) JP7066728B2 (en)
KR (3) KR20230151050A (en)
CN (2) CN110248951B (en)
AU (2) AU2018215203B2 (en)
CA (2) CA3197567A1 (en)
CO (1) CO2019009215A2 (en)
GE (1) GEP20237457B (en)
IL (3) IL295609B2 (en)
MX (2) MX2019009114A (en)
MY (1) MY201105A (en)
PH (1) PH12019550113A1 (en)
SG (2) SG11201906163TA (en)
TW (2) TWI808072B (en)
UA (1) UA127407C2 (en)
WO (1) WO2018144640A1 (en)
ZA (3) ZA201904336B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY190867A (en) * 2015-03-06 2022-05-13 Atea Pharmaceuticals Inc ? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
JP7066728B2 (en) * 2017-02-01 2022-05-13 アテア ファーマシューティカルズ， インコーポレイテッド Nucleotide hemi sulfate for the treatment of hepatitis C virus
CN112351799A (en) 2018-04-10 2021-02-09 阿堤亚制药公司 Treatment of HCV infected patients with cirrhosis
EP3890751A1 (en) * 2018-12-05 2021-10-13 ATEA Pharmaceuticals, Inc. Highly active drug combination for treatment of hepatitis c virus
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
WO2021216722A1 (en) * 2020-04-23 2021-10-28 Atea Pharmaceuticals, Inc. Stereoselective process of manufacture of purine phosphoramidates
CN112782311B (en) * 2020-12-30 2022-12-27 南京百泽医药科技有限公司 HPLC (high performance liquid chromatography) determination method for L-isopropyl alanine in propane phenol fumarate tenofovir
TW202245806A (en) * 2021-01-26 2022-12-01 美商亞堤製藥公司 Advantageous morphic form of at-527 hemi-sulfate salt
CN112940053B (en) * 2021-02-26 2022-08-12 江苏阿尔法药业股份有限公司 Preparation method of anti-HCV (hepatitis C Virus) medicine
WO2022266497A1 (en) * 2021-06-17 2022-12-22 Atea Pharmaceuticals, Inc. Advantageous anti-hcv combination therapy

Family Cites Families (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2297294C (en) 1989-05-15 2005-11-08 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Phosphonomethoxymethylpurine/pyrimidine derivatives
IT1249732B (en) 1991-11-26 1995-03-09 Angeletti P Ist Richerche Bio ANTISENSE OLIGONUCLEOTIDES.
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
ATE271063T1 (en) 1996-10-16 2004-07-15 Icn Pharmaceuticals PURINE-L-NUCLEOSIDES, THEIR ANALOGUES AND USES
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
BR9908270A (en) 1998-02-25 2004-06-29 Univ Emory 2-Fluoro-nucleosides, pharmaceutical compositions and their uses
IN191496B (en) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
DE60136620D1 (en) 2000-04-13 2009-01-02 Pharmasset Inc 3 OR 2 HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF VIRUS INFECTIONS
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
CN1646141B (en) 2000-10-18 2014-06-25 吉利德制药有限责任公司 Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
EP2145965A1 (en) 2000-10-18 2010-01-20 Pharmasset, Inc. Multiplex quantification of nucleic acids in diseased cells
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
MXPA03006514A (en) 2001-01-22 2004-12-02 Merck & Co Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase.
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
GB0112617D0 (en) 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
EP1478322A4 (en) 2001-06-22 2007-08-08 Pharmasset Ltd Beta-2'-OR 3'-HALONUCLEOSIDES
AU2002330154A1 (en) 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
AU2002351077A1 (en) 2001-11-05 2003-05-19 Exiqon A/S Oligonucleotides modified with novel alpha-l-rna analogues
US7388002B2 (en) 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
AU2002365234B2 (en) 2001-12-14 2009-01-29 Pharmasset Inc N4-acylcytosine nucleosides for treatment of viral infections
AU2002360697B2 (en) 2001-12-20 2009-04-23 Beth Israel Deaconess Medical Center Treatment of EBV and KHSV infection and associated abnormal cellular proliferation
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
AU2003217863B9 (en) 2002-02-28 2009-10-29 Biota Scientific Management Pty Ltd Nucleotide mimics and their prodrugs
EP1501850A2 (en) 2002-05-06 2005-02-02 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
PL374792A1 (en) 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
WO2004002999A2 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
AU2003248748A1 (en) 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
WO2004009020A2 (en) 2002-07-24 2004-01-29 Merck & Co., Inc. Pyrrolopyrimidine thionucleoside analogs as antivirals
US20040067877A1 (en) 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
CA2494340C (en) 2002-08-01 2012-01-24 Pharmasset Inc. Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections
AU2003259735A1 (en) 2002-08-08 2004-02-25 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
KR20050088079A (en) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-branched nucleosides and flaviviridae mutation
TWI294882B (en) 2002-12-09 2008-03-21 Hoffmann La Roche Anhydrous crystalline azido cytosine hemisulfate derivative
AR043006A1 (en) 2003-02-12 2005-07-13 Merck & Co Inc PROCESS TO PREPARE RAMIFIED RIBONUCLEOSIDS
WO2004074350A2 (en) * 2003-02-21 2004-09-02 Hetero Drugs Limited Bicalutamide polymorphs
EP1613261A4 (en) 2003-04-09 2011-01-26 Novo Nordisk As Intracellular formation of peptide conjugates
ATE490788T1 (en) 2003-04-25 2010-12-15 Gilead Sciences Inc ANTIVIRAL PHOSPHONATE ANALOGUE
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2005020884A2 (en) 2003-05-14 2005-03-10 Idenix (Cayman) Limited Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
CA2734052A1 (en) * 2003-05-30 2005-01-13 Pharmasset, Inc. Modified fluorinated nucleoside analogues
EP1644395B1 (en) 2003-06-19 2006-11-22 F. Hoffmann-La Roche Ag Processes for preparing 4'azido nucleoside derivatives
PL1658302T3 (en) 2003-07-25 2011-03-31 Idenix Pharmaceuticals Inc Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
DE10335061B4 (en) 2003-07-31 2005-11-17 Wacker-Chemie Gmbh Process for the preparation of OH-protected [4- (2,6-damino-9H-purin-9-yl) -1,3-dioxolan-2-yl] methanol derivatives
MXPA06002198A (en) 2003-08-27 2007-08-14 Biota Scient Management Novel tricyclic nucleosides or nucleotides as therapeutic agents.
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
WO2005123087A2 (en) 2004-06-15 2005-12-29 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
US7560434B2 (en) 2004-06-22 2009-07-14 Biocryst Pharmaceuticals, Inc. AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
US20070265222A1 (en) 2004-06-24 2007-11-15 Maccoss Malcolm Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
US20050287892A1 (en) 2004-06-29 2005-12-29 Willie Fouse Nonwoven-elastomeric laminate with improved bonding between elastomer and nonwoven web
CN101023094B (en) 2004-07-21 2011-05-18 法莫赛特股份有限公司 Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
RU2433124C2 (en) 2004-09-14 2011-11-10 Фармассет, Инк. Methods of producing 2'-fluoro-2'-alkyl-substituted or other substituted ribofuranosyl pyrimidines and purines and derivatives thereof
WO2006050161A2 (en) 2004-10-29 2006-05-11 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
EP1827460A4 (en) 2004-12-09 2012-03-14 Univ Minnesota Nucleosides with antiviral and anticancer activity
BRPI0518984A2 (en) 2004-12-10 2008-12-16 Univ Emory 2 'and 3' substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cell proliferation
WO2006063717A2 (en) 2004-12-16 2006-06-22 Febit Biotech Gmbh Polymerase-independent analysis of the sequence of polynucleotides
US8802840B2 (en) 2005-03-08 2014-08-12 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
WO2006102533A2 (en) 2005-03-23 2006-09-28 Neopharm, Inc. Pharmaceutically active lipid-based formulation of nucleoside-lipid conjugates
US7514410B2 (en) 2005-03-29 2009-04-07 Biocryst Pharmaceuticals, Inc. Hepatitis C therapies
WO2006130217A2 (en) 2005-04-01 2006-12-07 The Regents Of The University Of California Substituted phosphate esters of nucleoside phosphonates
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
US7632821B2 (en) 2005-08-09 2009-12-15 Merck & Co., Inc. Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection
US20090118223A1 (en) 2005-08-12 2009-05-07 Erion Mark D Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives
CN101287472B (en) 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 Antiviral 4'-substituted pre-nucleotide phosphoramidates
WO2007095269A2 (en) 2006-02-14 2007-08-23 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
WO2007130783A2 (en) 2006-05-03 2007-11-15 Chimerix, Inc. Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
WO2008005542A2 (en) 2006-07-07 2008-01-10 Gilead Sciences, Inc., Antiviral phosphinate compounds
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
CA2666098C (en) 2006-10-10 2012-09-25 Steven D. Axt Preparation of nucleosides ribofuranosyl pyrimidines
PL216525B1 (en) 2006-10-17 2014-04-30 Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk 5'-0-[(N-acyl) amidophosphate] - and 5'-0- [(N-acyl) amidothiophosphate]- and 5'-0- [N-acyl) amidodithiophosphate] and 5'-0- [N-acyl) amidoselenophosphate] - nucleosides and method for their manufacture
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
AU2007338899A1 (en) 2006-12-20 2008-07-03 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
EP2124555B1 (en) 2007-01-05 2015-07-08 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
CA2674589A1 (en) 2007-01-12 2008-07-24 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
AU2008210411A1 (en) 2007-01-31 2008-08-07 Alios Biopharma, Inc. 2-5A derivatives and their use as anti-cancer, anti-viral and anti-parasitic agents
WO2008100447A2 (en) 2007-02-09 2008-08-21 Gilead Sciences, Inc. Nucleoside analogs for antiviral treatment
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
ES2393038T3 (en) 2007-05-10 2012-12-18 Biocryst Pharmaceuticals, Inc. Tretrahydrofuro [3,4-D] dioxolane compounds for use in the treatment of viral infections and cancer
US20100279969A1 (en) 2007-05-14 2010-11-04 Rfs Pharma, Llc Azido purine nucleosides for treatment of viral infections
SI2014771T1 (en) 2007-06-25 2015-04-30 Anadys Pharmaceuticals, Inc. Continuous enzymatic hydrolysis process
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
US20090060872A1 (en) 2007-08-31 2009-03-05 Idenix Pharmaceuticals, Inc. Phosphadiazine hcv polymerase inhibitors v
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
WO2009086201A1 (en) 2007-12-21 2009-07-09 Alios Biopharma, Inc. 2-5a analogs and their use as anti-cancer, anti-viral and anti- paras iti c agents
US20090176732A1 (en) 2007-12-21 2009-07-09 Alios Biopharma Inc. Protected nucleotide analogs
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
EP3042660A3 (en) 2008-04-15 2016-10-26 RFS Pharma, LLC. Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
PT2280973E (en) 2008-04-23 2013-02-04 Gilead Sciences Inc Carba-nucleoside analogs for antiviral treatment
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
AR072428A1 (en) 2008-07-01 2010-08-25 Medivir Ab PIRIMIDIN DERIVATIVES NUCLEOTID INHIBITORS OF VIRUS POLYMERASES OF HEPATITIS C (HCV), PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHOD TO PREPARE THEM.
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
AU2009282567B2 (en) 2008-08-20 2014-10-02 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TW201020245A (en) 2008-08-20 2010-06-01 Schering Corp Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AU2009282574B2 (en) 2008-08-20 2014-08-21 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
PA8852101A1 (en) 2008-12-08 2010-07-27 Medivir Ab URACIL CYCLOPROPYLL NUCLEOTIDES
US8815829B2 (en) 2008-12-09 2014-08-26 Rfs Pharma, Llc 3′-azido purine nucleotide prodrugs for treatment of viral infections
NZ593648A (en) * 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
CL2009002206A1 (en) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compounds derived from pyrrolo - (2-3-d] -pyrimidin-7 (6h) -tetrahydrofuran-2-yl phosphonamidate, pharmaceutical composition; and its use in the treatment of viral diseases.
EA201100851A1 (en) * 2008-12-23 2012-04-30 Фармассет, Инк. NUCLEOSIDE ANALOGUES
PE20120013A1 (en) 2009-01-09 2012-02-02 Univ Cardiff GUANOSINE-DERIVED PHOSPHORAMIDATE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS
WO2010091386A2 (en) 2009-02-06 2010-08-12 Rfs Pharma, Llc Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
EA025085B1 (en) 2009-02-10 2016-11-30 Джилид Сайэнс, Инк. Carba-nucleoside analogs for antiviral treatment
AR075584A1 (en) 2009-02-27 2011-04-20 Intermune Inc THERAPEUTIC COMPOSITIONS THAT INCLUDE beta-D-2'-DESOXI-2'-FLUORO-2'-C-METHYLYCTIDINE AND A CARDIEX ISOINDOL ACID DERIVATIVE AND ITS USES. COMPOUND.
JP5690286B2 (en) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド Phosphothiophene and phosphothiazole HCV polymerase inhibitors
KR20110128947A (en) 2009-03-20 2011-11-30 앨리오스 바이오파마 인크. Substituted nucleoside and nucleotide analogs
WO2010108135A1 (en) 2009-03-20 2010-09-23 Alios Biopharma, Inc. Protected nucleotide analogs
JO3027B1 (en) 2009-05-14 2016-09-05 Janssen Products Lp Uracyl Spirooxetane Nucleosides
TWI576352B (en) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2264169A1 (en) 2009-06-15 2010-12-22 Qiagen GmbH Modified siNA
US20100331397A1 (en) 2009-06-24 2010-12-30 Alios Biopharma, Inc. 2-5a analogs and their methods of use
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US8552021B2 (en) 2009-09-29 2013-10-08 Janssen Products, L.P. Phosphoramidate derivatives of nucleosides
US8816074B2 (en) 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
JP5779799B2 (en) 2009-11-16 2015-09-16 ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド 2'-Fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections
MY159958A (en) 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
US8563530B2 (en) * 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
BR112012024884A2 (en) 2010-03-31 2016-10-18 Gilead Pharmasset Llc stereo-selective synthesis of phosphorus-containing assets
MX2012011222A (en) 2010-04-01 2013-01-18 Centre Nat Rech Scient Compounds and pharmaceutical compositions for the treatment of viral infections.
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
BR112013001267A2 (en) 2010-07-19 2016-05-17 Gilead Sciences Inc Methods for Preparing Diasteromerically Pure Phosphoramidate Prodrugs
CA2809261A1 (en) 2010-08-26 2012-03-01 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis c virus
WO2012040124A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
PE20140608A1 (en) 2010-09-22 2014-06-12 Alios Biopharma Inc REPLACED NUCLEOTIDE ANALOGS
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
WO2012041965A1 (en) 2010-09-29 2012-04-05 Universidad Nacional De Quilmes Process for producing dialkylphosphotriesters of nucleosides by enzymatic transesterification and deprotection thereof for producing nucleoside monophosphates
WO2012048013A2 (en) 2010-10-06 2012-04-12 Inhibitex, Inc. Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections
EP2638054B1 (en) 2010-11-10 2014-12-03 Janssen Products, L.P. Uracyl spirooxetane nucleoside phosphoramidates
AR084044A1 (en) 2010-11-30 2013-04-17 Pharmasset Inc 2’-ESPIRO-NUCLEOSID COMPOUNDS
TW201701876A (en) * 2010-12-20 2017-01-16 吉李德科學股份有限公司 Methods for treating HCV
AU2011349278C1 (en) 2010-12-22 2017-01-19 Alios Biopharma, Inc. Cyclic nucleotide analogs
WO2012092484A2 (en) 2010-12-29 2012-07-05 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
US9095599B2 (en) 2011-01-03 2015-08-04 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
WO2012125900A1 (en) 2011-03-16 2012-09-20 Enanta Pharmaceuticals, Inc. 2'-allene-substituted nucleoside derivatives
WO2012154321A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
BR112013026345A2 (en) 2011-04-13 2019-04-24 Merck Sharp & Dohe Corp. compound, pharmaceutical composition, use of a compound, and method for treating an hcv infected patient
US8877733B2 (en) 2011-04-13 2014-11-04 Gilead Sciences, Inc. 1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
BR112013029761A2 (en) 2011-05-19 2017-03-21 Univ Emory purine monophosphate prodrugs for treatment of viral infections
EP2731433A4 (en) 2011-07-13 2014-12-31 Merck Sharp & Dohme 5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
AU2012290089B2 (en) 2011-08-01 2016-09-29 Mbc Pharma, Inc. Vitamin B6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
WO2013039920A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
AU2012308900A1 (en) 2011-09-12 2013-05-09 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013044030A1 (en) 2011-09-23 2013-03-28 Enanta Pharmaceuticals, Inc. 2'-chloroacetylenyl substituted nucleoside derivatives
EP2768838A1 (en) 2011-10-14 2014-08-27 IDENIX Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
BR112014009634A2 (en) * 2011-10-19 2017-05-09 Mercator Medsystems Inc preparation and therapeutic agent
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013090420A2 (en) 2011-12-12 2013-06-20 Catabasis Pharmaceuticals, Inc. Fatty acid antiviral conjugates and their uses
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc Substituted phosphorothioate nucleotide analogs
CA2864098A1 (en) 2012-02-14 2013-08-22 University Of Georgia Research Foundation, Inc. Spiro[2.4]heptanes for treatment of flaviviridae infections
SI2820016T1 (en) * 2012-02-27 2017-11-30 Bristol-Myers Squibb Company N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta (b)pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo (4, 5 -b)pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt
WO2013142159A1 (en) 2012-03-21 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
NZ630800A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Methods of preparing substituted nucleotide analogs
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
US9809616B2 (en) 2012-10-29 2017-11-07 Emory University Pyrimidine nucleosides and their monophosphate prodrugs for the treatment of viral infections and cancer
US8846638B2 (en) 2012-05-17 2014-09-30 Enanta Pharmaceuticals, Inc. Macrocyclic nucleoside phosphoramidate derivatives
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
AP3913A (en) 2012-05-22 2016-11-26 Idenix Pharamaceuticals Inc D-amino acid compounds for liver disease
CN104640444B (en) 2012-06-16 2016-12-14 河南美泰宝生物制药有限公司 Double liver target phosphoramidates and aminophosphonic acid ester prodrugs
EP2870169A1 (en) 2012-07-03 2015-05-13 Bristol-Myers Squibb Company Process for preparing diastereomerically enriched phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
WO2014047117A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Process for preparing phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
EP2900682A1 (en) 2012-09-27 2015-08-05 IDENIX Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
WO2014063019A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
MX2015006195A (en) 2012-11-16 2015-12-08 Univ Cardiff Process for preparing nucleoside prodrugs.
GB201220843D0 (en) 2012-11-20 2013-01-02 Univ College Cork Nat Univ Ie Compound
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
WO2014100498A1 (en) 2012-12-21 2014-06-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
KR102327888B1 (en) 2012-12-21 2021-11-17 얀센 바이오파마, 인코퍼레이트. Substituted nucleosides, nucleotides and analogs thereof
DK2950786T3 (en) 2013-01-31 2020-02-17 Gilead Pharmasset Llc COMBINATION FORMATION OF TWO ANTIVIRAL COMPOUNDS
WO2014124430A1 (en) 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
CN105377868A (en) 2013-04-12 2016-03-02 艾其林医药公司 Highly active nucleoside derivative for the treatment of HCV
CN103435672A (en) 2013-04-25 2013-12-11 刘沛 Structure and synthesis of novel nucleoside phosphate prodrug containing substituted benzyl
EP3013340B9 (en) 2013-06-26 2023-10-04 Janssen Pharmaceuticals, Inc. Substituted nucleosides, nucleotides and analogs thereof
US20150011481A1 (en) 2013-07-02 2015-01-08 Abbvie Inc. Methods for Treating HCV
EP3043803B1 (en) 2013-09-11 2022-04-27 Emory University Nucleotide and nucleoside compositions and their uses
US8889701B1 (en) 2013-10-11 2014-11-18 Alla Chem, Llc Substituted (S)-(2R,3R,5R)-3-hydroxy-(5-pyrimidin-1-yl)tetrahydrofuran-2-ylmethyl aryl phosphoramidate
SG10201804835VA (en) 2013-10-11 2018-07-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
EP3063165A1 (en) 2013-11-01 2016-09-07 Idenix Pharmaceuticals LLC D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
US10030044B2 (en) 2013-11-27 2018-07-24 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
US20150150897A1 (en) 2013-12-02 2015-06-04 Gilead Pharmasset Llc Methods of treating hepatitis c virus infection in subjects with cirrhosis
WO2015095305A1 (en) 2013-12-17 2015-06-25 Idenix Pharmaceuticals, Inc. Production of cyclic phosphate, phosphoramidate, thiophosphate, and phosphonate nucleoside compounds
WO2015158913A1 (en) 2014-04-17 2015-10-22 Katholieke Universiteit Leuven Novel antiviral and antitumoral compounds
HUE051986T2 (en) 2014-06-24 2021-04-28 Janssen Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof for use in the treatment of viral infection
AU2015280234B2 (en) 2014-06-24 2021-04-01 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN107108676A (en) 2014-09-15 2017-08-29 美迪维尔公司 Method for preparing the pure phosphoramidate prodrug of diastereo-isomerism
CN105646629A (en) 2014-11-25 2016-06-08 广州市恒诺康医药科技有限公司 L-nucleoside compounds and application thereof
MA41441A (en) 2014-12-19 2017-12-12 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUES OF THEM
MA41213A (en) 2014-12-19 2017-10-24 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUES OF THEM
MY190867A (en) * 2015-03-06 2022-05-13 Atea Pharmaceuticals Inc ? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
WO2016145142A1 (en) 2015-03-10 2016-09-15 Emory University Nucleotide and nucleoside therapeutics compositions and uses related thereto
CN106188192B (en) 2015-04-29 2019-09-10 刘沛 Nucleosides phosphoramidic acid/the phosphate derivatives and its medical usage of the amino-acid ester containing D-
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018009623A1 (en) 2016-07-08 2018-01-11 Atea Pharmaceuticals, Inc. β-D-2'-DEOXY-2'-SUBSTITUTED-4'-SUBSTITUTED-2-SUBSTITUTED-N6-SUBSTITUTED-6-AMINOPURINE NUCLEOTIDES FOR THE TREATMENT OF PARAMYXOVIRUS AND ORTHOMYXOVIRUS INFECTIONS
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EA037868B1 (en) 2016-09-07 2021-05-28 Атеа Фармасьютикалс, Инк. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
JP7066728B2 (en) * 2017-02-01 2022-05-13 アテア ファーマシューティカルズ， インコーポレイテッド Nucleotide hemi sulfate for the treatment of hepatitis C virus
CN112351799A (en) 2018-04-10 2021-02-09 阿堤亚制药公司 Treatment of HCV infected patients with cirrhosis
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021216722A1 (en) 2020-04-23 2021-10-28 Atea Pharmaceuticals, Inc. Stereoselective process of manufacture of purine phosphoramidates
KR20230053640A (en) 2020-08-19 2023-04-21 아테아 파마슈티컬즈, 인크. Stereoselective Preparation of Selected Purine Phosphoramidates
WO2022076903A1 (en) 2020-10-09 2022-04-14 Atea Pharmaceuticals, Inc. Niran interfering drugs for sars-cov-2 mutant therapy
TW202245806A (en) 2021-01-26 2022-12-01 美商亞堤製藥公司 Advantageous morphic form of at-527 hemi-sulfate salt

Also Published As

Publication number Publication date
AU2018215203B2 (en) 2022-12-08
US20200331954A1 (en) 2020-10-22
UA127407C2 (en) 2023-08-16
US10519186B2 (en) 2019-12-31
RU2019127284A3 (en) 2021-08-04
CO2019009215A2 (en) 2019-08-30
US20200087339A1 (en) 2020-03-19
KR20190113864A (en) 2019-10-08
JP2020505423A (en) 2020-02-20
US12006340B2 (en) 2024-06-11
CN110248951A (en) 2019-09-17
ZA202104494B (en) 2023-01-25
ZA201904336B (en) 2020-12-23
US10894804B2 (en) 2021-01-19
US20180215776A1 (en) 2018-08-02
IL288737A (en) 2022-02-01
SG11201906163TA (en) 2019-08-27
KR20210151247A (en) 2021-12-13
AU2018215203A1 (en) 2019-07-18
KR102335193B1 (en) 2021-12-03
CN115477679A (en) 2022-12-16
EP3577124A4 (en) 2021-01-06
KR20230151050A (en) 2023-10-31
GEP20237457B (en) 2023-01-10
TW201832770A (en) 2018-09-16
JP7066728B2 (en) 2022-05-13
CA3197567A1 (en) 2018-08-09
RU2019127284A (en) 2021-03-02
US20210087217A1 (en) 2021-03-25
BR112019014738A8 (en) 2022-10-11
AU2022271421A1 (en) 2022-12-22
ZA202207262B (en) 2023-11-29
IL268077B (en) 2022-01-01
KR102592899B1 (en) 2023-10-24
TW202337472A (en) 2023-10-01
CA3048033C (en) 2023-06-20
EP3577124A1 (en) 2019-12-11
IL295609A (en) 2022-10-01
JP2022078216A (en) 2022-05-24
IL295609B1 (en) 2023-07-01
NZ754996A (en) 2022-03-25
MX2019009114A (en) 2019-10-09
IL288737B (en) 2022-09-01
IL268077A (en) 2019-09-26
US20210277045A1 (en) 2021-09-09
SG10202012214WA (en) 2021-01-28
US20240018179A1 (en) 2024-01-18
US10906928B2 (en) 2021-02-02
PH12019550113A1 (en) 2019-12-02
BR112019014738A2 (en) 2020-03-10
CA3048033A1 (en) 2018-08-09
WO2018144640A1 (en) 2018-08-09
IL295609B2 (en) 2023-11-01
MY201105A (en) 2024-02-06
CN110248951B (en) 2022-10-28
TWI808072B (en) 2023-07-11

Similar Documents

Publication Publication Date Title
MX2022009352A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus.
MX2022011756A (en) Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor.
EA201491548A1 (en) 2'-SUBSTITUTED CARBANECULOSE ANALOGUES FOR ANTI-VIRUS TREATMENT
NZ703064A (en) Inhibitors of hepatitis c virus
PH12015502230A1 (en) Novel viral replication inhibitors
EA201590457A1 (en) SULFAMOIL-Arylamides and Their Use as Medicinal Products for the Treatment of Hepatitis B
EA026667B9 (en) Pharmaceutical composition for treating hepatitis c virus
MX2019002541A (en) Anti-influenza virus pyrimidine derivative.
NZ631726A (en) Therapeutic compounds for the treatment of viral infections
MY195364A (en) Amide Compounds for the Treatment Of Hiv
MY182771A (en) Viral replication inhibitors
PH12017501598A1 (en) �-D-2`-DEOXY-2`a-FLUORO-2`-�-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
MX2016004492A (en) Inhibitors of human immunodeficiency virus replication.
MX371093B (en) Microrna compounds and methods for modulating mir-122.
JO3281B1 (en) Benzofuran Compounds for the Treatment of Hepatitis C Virus Infections
PH12016502039A1 (en) Potent and selective inhibitors of hepatitis c virus
PH12019502376A1 (en) Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
WO2014116772A3 (en) Squaric derivatives for the treatment of hepatitis c
IN2011CH03893A (en)
MX2016012104A (en) Cyano containing azabenzofuran compounds for the treatment of hepatitis c.
PH12019501907A1 (en) Novel viral replication inhibitors
IN2014DN10683A (en)
EA201991810A1 (en) HEMISULPHATE NUCLEOTIDE SALT FOR TREATMENT OF HEPATITIS C VIRUS